Moexipril in postmenopausal women with arterial hypertension
Aim. To assess moexipril clinical efficacy, safety, and target organ protection in postmenopausal women. Material and methods. An open, randomized, non-comparative trial involved 32 postmenopausal women (mean age 63.17±0.87 years), with arterial hypertension (AH) mean duration of 10.4±2.3 years, Six...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2005-02-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/903 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849250447587540992 |
|---|---|
| author | M. G. Glezer E. B. Tkhostova M. A. Demidova Yu. B. Belousov |
| author_facet | M. G. Glezer E. B. Tkhostova M. A. Demidova Yu. B. Belousov |
| author_sort | M. G. Glezer |
| collection | DOAJ |
| description | Aim. To assess moexipril clinical efficacy, safety, and target organ protection in postmenopausal women. Material and methods. An open, randomized, non-comparative trial involved 32 postmenopausal women (mean age 63.17±0.87 years), with arterial hypertension (AH) mean duration of 10.4±2.3 years, Sixteen-week moexipril therapy influence on blood pressure (BP) level (office measurement and 24-hour BP monitoring), vascular function, and microalbuminuria (MAU) in morning urine portion, was investigated. Results. Target BP level was achieved in 29 out of 30 patients: 9 women received 7.5 mg/d of moexipril, 13–15 mg/d, 8–15 mg/d, plus hydrochlorthiazide (12.5 mg/d); 2 women were excluded due to adverse events. Office BP level declined from 164.33±1.45/94.50±0.89 mm Hg to 133.5±0.57/81.5±0.65 mm Hg. In 24-hour BP monitoring, day- and nighttime BP levels decreased, as well as pulse BP, and BP variability. In reactive hyperemia and nitroglycerine tests, vasodilatation increased by approximately 50% and 40%, respectively. MAU significantly reduced from 28.28±3.94 to 8.10±1.00 mg/l (p<0.001). Conclusion. Moexipril therapy demonstrated substantial antihypertensive and organoprotective effects in postmenopausal women with AH, being at the same time metabolically neutral. |
| format | Article |
| id | doaj-art-3295a0b4b9954e0680d8733ab16222b2 |
| institution | Kabale University |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2005-02-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-3295a0b4b9954e0680d8733ab16222b22025-08-20T03:57:17Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252005-02-01411419618Moexipril in postmenopausal women with arterial hypertensionM. G. Glezer0E. B. Tkhostova1M. A. Demidova2Yu. B. Belousov3I.M. Sechenov Moscow Medical Academy, MoscowRussian State Medical University, MoscowRussian State Medical University, MoscowRussian State Medical University, MoscowAim. To assess moexipril clinical efficacy, safety, and target organ protection in postmenopausal women. Material and methods. An open, randomized, non-comparative trial involved 32 postmenopausal women (mean age 63.17±0.87 years), with arterial hypertension (AH) mean duration of 10.4±2.3 years, Sixteen-week moexipril therapy influence on blood pressure (BP) level (office measurement and 24-hour BP monitoring), vascular function, and microalbuminuria (MAU) in morning urine portion, was investigated. Results. Target BP level was achieved in 29 out of 30 patients: 9 women received 7.5 mg/d of moexipril, 13–15 mg/d, 8–15 mg/d, plus hydrochlorthiazide (12.5 mg/d); 2 women were excluded due to adverse events. Office BP level declined from 164.33±1.45/94.50±0.89 mm Hg to 133.5±0.57/81.5±0.65 mm Hg. In 24-hour BP monitoring, day- and nighttime BP levels decreased, as well as pulse BP, and BP variability. In reactive hyperemia and nitroglycerine tests, vasodilatation increased by approximately 50% and 40%, respectively. MAU significantly reduced from 28.28±3.94 to 8.10±1.00 mg/l (p<0.001). Conclusion. Moexipril therapy demonstrated substantial antihypertensive and organoprotective effects in postmenopausal women with AH, being at the same time metabolically neutral.https://cardiovascular.elpub.ru/jour/article/view/903womenarterial hypertensionpostmenopausemoexiprilmicroalbuminuriaendothelial dysfunction |
| spellingShingle | M. G. Glezer E. B. Tkhostova M. A. Demidova Yu. B. Belousov Moexipril in postmenopausal women with arterial hypertension Кардиоваскулярная терапия и профилактика women arterial hypertension postmenopause moexipril microalbuminuria endothelial dysfunction |
| title | Moexipril in postmenopausal women with arterial hypertension |
| title_full | Moexipril in postmenopausal women with arterial hypertension |
| title_fullStr | Moexipril in postmenopausal women with arterial hypertension |
| title_full_unstemmed | Moexipril in postmenopausal women with arterial hypertension |
| title_short | Moexipril in postmenopausal women with arterial hypertension |
| title_sort | moexipril in postmenopausal women with arterial hypertension |
| topic | women arterial hypertension postmenopause moexipril microalbuminuria endothelial dysfunction |
| url | https://cardiovascular.elpub.ru/jour/article/view/903 |
| work_keys_str_mv | AT mgglezer moexiprilinpostmenopausalwomenwitharterialhypertension AT ebtkhostova moexiprilinpostmenopausalwomenwitharterialhypertension AT mademidova moexiprilinpostmenopausalwomenwitharterialhypertension AT yubbelousov moexiprilinpostmenopausalwomenwitharterialhypertension |